WHAT YOU NEED TO KNOW
  • The REDUCE trial tested spironolactone in stroke survivors whose blood pressure remained elevated despite treatment.
  • After three months, average top blood pressure readings were about 126 with spironolactone, compared with approximately 133 under usual care.
  • High potassium and dizziness are potential safety concerns, particularly for people with kidney problems or those taking certain medications.
  • The trial enrolled 160 participants, and about 15% lacked blood pressure readings at the three month mark.

A common, low cost medication may help stroke survivors whose blood pressure remains elevated despite treatment. New findings suggest that adding spironolactone to regular care can produce a meaningful reduction in blood pressure within months.

The research, known as the REDUCE trial, examined whether spironolactone could improve blood pressure control after a stroke. The medication is commonly described as a water pill because it helps the body eliminate excess salt and water.

The findings were presented at the American Heart Association’s Scientific Sessions, held Nov. 6 through 9, 2026, in Chicago. Researchers focused on stroke survivors who continued to have elevated blood pressure despite receiving treatment.

Participants were divided into two groups for the trial. One group added spironolactone to its regular treatment, while the other group continued receiving usual care after a stroke.

Researchers then tracked blood pressure readings taken by participants at home over the following six months. The monitoring was intended to determine whether adding spironolactone made a measurable difference compared with usual care alone.

After three months, the average top blood pressure reading was nearly eight points lower among participants taking spironolactone. The average was about 126 in the spironolactone group, compared with approximately 133 among those receiving usual care.

Researchers reported that adding the medication to regular care after a stroke lowered blood pressure more effectively than usual treatment alone. The results point to a possible additional treatment option for patients whose readings remain elevated.

Dr. Alfred Joshua, a California based, board certified emergency physician and former chief medical officer, was not involved in the research. He described the findings as encouraging while emphasizing that they do not establish whether spironolactone prevents another stroke.

Do you read nutrition labels before buying packaged foods?

By completing the poll, you agree to receive emails from Being Healthy News, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.

“We already know that controlling blood pressure lowers the risk of another stroke,” Joshua told Fox News Digital. “This study measured blood pressure, so whether adding spironolactone leads to fewer repeat strokes is still an open question.”

Spironolactone works by helping the body remove extra salt and water, according to the U.S. National Library of Medicine. That process can lower blood pressure in patients who need additional help controlling their readings.

The medication also causes the body to retain potassium, according to its prescribing information. Patients taking spironolactone therefore need to have their potassium levels checked while using the drug.

Joshua warned that elevated potassium is one of the medication’s main safety concerns because it can develop without symptoms. The risk may be higher among people with kidney problems and those taking certain medications or potassium supplements.

Spironolactone can also lower blood pressure enough to cause dizziness, Joshua said. Those potential effects make clinical guidance and monitoring important when patients are considering whether the drug is appropriate.

“If your blood pressure is still high after a stroke, bring your home readings to your clinician and ask whether this medication is a good fit,” Joshua advised.

The REDUCE trial ended early after enrolling 160 participants rather than the planned 200. Researchers also noted that about 15% of participants did not have blood pressure readings available at the three month mark.

Participants taking spironolactone were using slightly more blood pressure medications overall than those receiving usual care. The study was not designed to determine whether spironolactone prevents another stroke or heart attack.

Researchers said larger and longer studies are needed to answer that central question. For now, the trial shows improved blood pressure readings while leaving the effect on subsequent strokes and heart attacks unresolved.